Given that the W_Score was strongly related to the immune microenvironment, we further evaluated the power of the W_Score model in predicting patients’ responses to immunotherapy with PD-1/PD-L1 inhibitors, based on the anti-PD-1 cohort (GSE78220; metastatic melanoma) and anti-PD-L1 cohort (IMvigor210; advanced urothelial cancer). This evidence concerns the gene CD274 and metastatic melanoma.